SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
-9.67%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$340M
AUM Growth
+$340M
(-9.2%)
Cap. Flow
-$481K
Cap. Flow
% of AUM
-0.14%
Top 10 Holdings %
Top 10 Hldgs %
55.44%
Holding
66
New
16
Increased
14
Reduced
10
Closed
19
Top Buys
| 1 |
Immunocore
IMCR
|
$11.5M |
| 2 |
Immunovant
IMVT
|
$10.2M |
| 3 |
Merck
MRK
|
$10.2M |
| 4 |
GSK
GSK
|
$9.47M |
| 5 |
Arcellx
ACLX
|
$7.75M |
Top Sells
| 1 |
Insmed
INSM
|
$12.4M |
| 2 |
Eli Lilly
LLY
|
$11.7M |
| 3 |
Arcutis Biotherapeutics
ARQT
|
$11.5M |
| 4 |
Roivant Sciences
ROIV
|
$8.89M |
| 5 |
Tarsus Pharmaceuticals
TARS
|
$8.08M |
Sector Composition
| 1 | Healthcare | 99.56% |
| 2 | Financials | 0.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Syndax Pharmaceuticals
SNDX
$1.41B
| $29M | 8.52% |
1,412,176
+311,188
| +28% | +$6.39M |
|
|
2
Roivant Sciences
ROIV
$8.15B
| $28.7M | 8.43% |
2,712,741
-841,103
| -24% | -$8.89M |
|
|
3
Immunovant
IMVT
$2.56B
| $26.7M | 7.85% |
1,011,879
+384,651
| +61% | +$10.2M |
|
4
Crinetics Pharmaceuticals
CRNX
$2.92B
| $24.7M | 7.25% |
551,095
-68,694
| -11% | -$3.08M |
|
5
Merus
MRUS
$4.98B
| $17.1M | 5.02% |
288,668
+54,797
| +23% | +$3.24M |
|
|
6
Arcellx
ACLX
$3.85B
| $15.5M | 4.55% |
280,709
+140,442
| +100% | +$7.75M |
|
7
Amicus Therapeutics
FOLD
$2.34B
| $14.8M | 4.36% |
1,495,047
-52,094
| -3% | -$517K |
|
|
8
Immunocore
IMCR
$1.62B
| $11.5M | 3.38% |
+339,351
| New | +$11.5M |
|
9
Applied Therapeutics
APLT
$71M
| $10.3M | 3.03% |
2,211,320
+194,304
| +10% | +$907K |
|
|
10
Merck
MRK
$210B
| $10.2M | 2.98% |
+81,508
| New | +$10.2M |
|
|
11
GSK
GSK
$79.9B
| $9.47M | 2.78% |
+245,933
| New | +$9.47M |
|
|
AUTL
12
Autolus Therapeutics
AUTL
$399M
| $9.27M | 2.72% |
2,662,732
-302,989
| -10% | -$1.05M |
|
|
13
Arcutis Biotherapeutics
ARQT
$1.86B
| $8.98M | 2.64% |
965,392
-1,240,507
| -56% | -$11.5M |
|
14
Cabaletta Bio
CABA
$133M
| $8.81M | 2.59% |
1,178,105
+174,189
| +17% | +$1.3M |
|
15
KalVista Pharmaceuticals
KALV
$678M
| $8.68M | 2.55% |
736,765
-424,295
| -37% | -$5M |
|
16
Biohaven
BHVN
$1.63B
| $8.1M | 2.38% |
233,255
+149,794
| +179% | +$5.2M |
|
17
VistaGen Therapeutics
VTGN
$102M
| $5.85M | 1.72% |
1,848,582
| – | – |
|
18
Immatics
IMTX
$619M
| $5.84M | 1.72% |
502,207
+10,281
| +2% | +$119K |
|
19
Denali Therapeutics
DNLI
$2.23B
| $5.83M | 1.71% |
+251,010
| New | +$5.83M |
|
|
20
Insmed
INSM
$28.8B
| $5.83M | 1.71% |
86,980
-185,468
| -68% | -$12.4M |
|
21
Celldex Therapeutics
CLDX
$1.47B
| $5.35M | 1.57% |
+144,467
| New | +$5.35M |
|
22
Larimar Therapeutics
LRMR
$310M
| $5.11M | 1.5% |
704,349
-36,528
| -5% | -$265K |
|
23
TScan Therapeutics
TCRX
$102M
| $4.94M | 1.45% |
+845,069
| New | +$4.94M |
|
24
Edgewise Therapeutics
EWTX
$1.51B
| $4.88M | 1.43% |
+271,057
| New | +$4.88M |
|
25
Corbus Pharmaceuticals
CRBP
$115M
| $4.59M | 1.35% |
+101,479
| New | +$4.59M |
|